2024
DOI: 10.3233/bd-230032
|View full text |Cite
|
Sign up to set email alerts
|

Use of axillary ultrasound to guide breast cancer management in the genomic assay era

Geok Hoon Lim,
John Carson Allen,
Yien Sien Lee
et al.

Abstract: INTRODUCTION: Chemotherapy is conventionally offered to non-stage IV breast cancer patients with metastatic nodes. However, the RxPONDER trial showed that chemotherapy can be omitted in selected patients with 1–3 metastatic nodes if the 21-gene assay recurrence score is ≤25. We aimed to investigate if axillary ultrasound can identify this group of patients with limited nodal burden so that they can undergo upfront surgery followed by gene assay testing, to potentially avoid chemotherapy. METHODS: T1-3, node po… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 15 publications
0
0
0
Order By: Relevance